Diabetes OD > Disease Management > T2DM > Metabolic Control > Anti-Hyperglycemic and Anti-Apoptotic Agents > Incretin Hormones > Incretin Mimetics > Liraglutide > Human Studies	Display all items Journal Articles Discussion Articles Comments Discussions Conferences/Workshops Availabilities Grants/Funds Information/News

(Journal Article): The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro.
 
Bregenholt S, Moldrup A, Blume N, Karlsen AE, Nissen Friedrichsen B, Tornhave D, Knudsen LB, Petersen JS
 
IN: Biochem Biophys Res Commun 2005; 330(2):577-584
Impact Factor(s) of Biochem Biophys Res Commun: 2.904 (2004), 2.836 (2003), 2.935 (2002), 2.946 (2001)

ABSTRACT: We here show that GLP-1 and the long-acting GLP-1 analogue, liraglutide, interfere with diabetes-associated apoptotic processes in the beta-cell. Studies using primary neonatal rat... Click HERE for details

(Journal Article): The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.
 
Harder H, Nielsen L, Tu DT, Astrup A
 
IN: Diabetes Care 2004; 27(8):1915-1921
Impact Factor(s) of Diabetes Care: 7.071 (2004), 7.501 (2003), 5.477 (2002), 5.404 (2001)

ABSTRACT: OBJECTIVE: Glucagon-like peptide (GLP)-1 is a gut hormone that exerts incretin effects and suppresses food intake in humans, but its therapeutic use is limited due to its short hal... Click HERE for details